Risk of bleeding in liver cirrhosis receiving direct oral anticoagulants: a systematic review and meta-analysis
Z Li, W Xu, L Wang, L Chai, W Ageno… - Thrombosis and …, 2023 - thieme-connect.com
Background Direct oral anticoagulants (DOACs) are effective for the management of
thromboembolic disorders. However, bleeding remains a major concern in cirrhotic patients …
thromboembolic disorders. However, bleeding remains a major concern in cirrhotic patients …
Recommendations for the safe use of direct oral anticoagulants in patients with cirrhosis based on a systematic review of pharmacokinetic, pharmacodynamic and …
MME Diesveld, DWMJ Pijnenburg, RA Weersink… - European journal of …, 2024 - Springer
Purpose The popularity of direct oral anticoagulants (DOACs) is increasing among patients
with cirrhosis. Cirrhosis has a major impact on the pharmacokinetics of drugs, potentially …
with cirrhosis. Cirrhosis has a major impact on the pharmacokinetics of drugs, potentially …
Efficacy and safety of direct oral anticoagulants versus traditional anticoagulants in patients with liver disease: a meta-analysis and systematic review
Q Zhou, X Liu, Y Tang, Z Gu, Y Wu, Y Yang, Y Tao… - 2024 - authorea.com
Abstract not-yet-known not-yet-known not-yet-known unknown Aims: Patients with liver
disease, particularly cirrhosis, are often excluded from clinical trials on anticoagulant …
disease, particularly cirrhosis, are often excluded from clinical trials on anticoagulant …